MOLECULAR HYBRIDISATION STRATEGIES IN ANTICANCER DRUG DESIGN: SYNTHETIC APPROACHES AND STRUCTURE-ACTIVITY RELATIONSHIP INSIGHTS

ANIKET BADULE[1], ROMIT BANSOD[2] ,GAYATRI THAKRE[3],MINAL KHOBRAGADE[4],TONIJ KANNAKE[5],PALLAVI SAHARE*[6]

[1,2,3,4,5,6] *Nagpur College of Pharmacy, Wanadongri, Nagpur 441110, Maharashtra, India*

ABSTRACT

The rational design of anticancer therapeutics through molecular hybridisation represents a paradigm shift from traditional single-target approaches towards multi-target drug discovery. This strategy involves the covalent integration of distinct pharmacophoric moieties within a unified molecular framework to achieve enhanced therapeutic efficacy whilst circumventing drug resistance mechanisms. This comprehensive review examines the theoretical foundations, synthetic methodologies, and structure-activity relationships governing the design of hybrid anticancer agents. We critically evaluate multi-target directed ligands (MTDLs), dual-mechanism hybrids, and targeting-warhead conjugates, emphasising their potential to address the complex molecular pathology of cancer. Contemporary evidence demonstrates that successful hybridisation strategies yield significant improvements in cytotoxic potency whilst maintaining favourable selectivity profiles. Synthetic challenges, including linker optimisation, stereochemical control, and scalability considerations, are analysed alongside innovative solutions. This review provides medicinal chemists with a systematic framework for the rational design of next-generation hybrid anticancer therapeutics.

Keywords: molecular hybridization , anticancer drug design, multi-target therapeutics, structure-activity relationship, synthetic chemistry

1. INTRODUCTION

Cancer continues to pose significant challenges to global healthcare systems, with approximately 19.3 million new cases diagnosed annually[1]. The molecular complexity underlying oncogenesis presents a formidable obstacle—genetic heterogeneity, adaptive resistance mechanisms, and intricate cellular signalling networks all contribute to treatment failures[2]. Traditional single-target approaches, whilst successful in many cases, often prove inadequate against this complexity. Consequently, researchers have increasingly turned to molecular hybridisation as an innovative drug design strategy. This approach offers promising opportunities to address current therapeutic limitations through simultaneous modulation of multiple targets[3].

Molecular hybridisation represents a departure from traditional drug discovery paradigms. Rather than relying on single-target approaches, this strategy involves covalently linking distinct pharmacophoric elements within a unified molecular framework[4]. The rationale behind this approach is compelling—cancer cells exhibit remarkable adaptability, often developing resistance through multiple pathways simultaneously[5]. By targeting several mechanisms at once, hybrid molecules may circumvent these resistance strategies more effectively than conventional drugs[6].

However, the practical implementation of hybridisation strategies presents considerable challenges. The successful fusion of different pharmacophores requires careful consideration of structure-activity relationships, synthetic accessibility, and the potential for antagonistic interactions between molecular components[7]. Despite these complexities, several hybrid agents have demonstrated promising results in preclinical studies, with some advancing to clinical evaluation[8].

This review provides a comprehensive analysis of molecular hybridisation strategies in anticancer drug design, examining the theoretical frameworks, synthetic methodologies, and clinical applications that define this rapidly evolving field. We present a systematic classification of hybrid approaches and critically evaluate their potential to address current limitations in cancer chemotherapy.

2. THEORETICAL FRAMEWORK AND DESING PRINCIPLES

2.1 Conceptual Basis of Molecular Hybridisation

The theoretical foundation of molecular hybridisation distinguishes it from conventional polypharmacology through the deliberate integration of discrete pharmacophoric units within a single molecular scaffold[9]. This approach addresses several fundamental limitations of traditional anticancer agents, including acquired resistance, narrow therapeutic windows, and insufficient selectivity for malignant cells versus healthy tissues[10].

The design of hybrid molecules requires consideration of target complementarity, wherein selected targets exhibit synergistic or additive therapeutic effects when modulated simultaneously[11]. Optimal target pairs often involve components within interconnected signalling cascades or regulators of distinct hallmarks of cancer, including sustained proliferative signalling, resistance to cell death, and angiogenesis[12].

2.2 Classification of Hybridisation Strategies

Contemporary hybrid anticancer agents can be systematically classified into four principal categories based on their structural architecture and biological targets:

Table 1. Classification and characteristics of anticancer hybrid strategies

Hybrid Type	Design Principle	Representative Examples	Primary Advantages
Multi-Target Directed Ligands (MTDLs)	Simultaneous engagement of multiple related targets	EGFR/HER2 inhibitors, HDAC/DNMT modulators	Synergistic activity, reduced resistance
Dual-Mechanism Hybrids	Integration of distinct mechanisms of action	DNA alkylator-topoisomerase inhibitor conjugates	Enhanced cytotoxicity, mechanistic complementarity
Targeting-Warhead Conjugates	Selective delivery of cytotoxic pyloads	Folate receptor-targeted drugs, PSMA conjugates	Improved selectivity, reduced systemic toxicity
Synergistic Pharmacophore Combinations	Cooperative activity of complementary fragments	Fragment-based hybrid designs	Novel mechanisms, scaffold expandability



Figure1: Schematic representation of hybrid classification with representative molecular architectures

2.3 Structure-Activity Relationship Considerations

The rational design of hybrid anticancer agents necessitates comprehensive understanding of SAR principles governing both individual pharmacophoric domains and their collective behaviour within the hybrid framework[13]. Critical determinants include linker design, spatial orientation of pharmacophores, conformational flexibility, and preservation of essential molecular recognition features[14].

Linker optimisation represents perhaps the most crucial aspect of hybrid design, as the connecting element must maintain appropriate spatial relationships between pharmacophoric domains whilst minimising interference with target binding[15]. Effective linkers typically exhibit sufficient flexibility to accommodate conformational requirements whilst maintaining chemical stability under physiological conditions[16].

3. SYNTHETIC METHODOLOGIES

3.1 Modern Synthetic Approaches

The construction of hybrid anticancer molecules demands sophisticated synthetic strategies that accommodate structural complexity whilst ensuring practical scalability[17]. Contemporary approaches predominantly utilise convergent synthetic methodologies, wherein discrete pharmacophoric fragments are prepared independently before strategic coupling[18].

Cross-Coupling Reactions:

Transition metal-catalysed cross-coupling reactions, particularly Suzuki-Miyaura, Sonogashira, and Buchwald-Hartwig transformations, have emerged as cornerstone methodologies for hybrid construction[19]. These reactions provide robust platforms for forming carbon-carbon and carbon-heteroatom bonds with exceptional selectivity and functional group tolerance.



Figure2 : Key cross-coupling reactions showing Suzuki-Miyaura, Sonogashira, and Buchwald-Hartwig mechanisms

Table 2. Comparison of synthetic methodologies for hybrid drug construction

Synthetic Method	Key Advantages	Primary Limitations	Hybrid Applications
Cross-Coupling Reactions	High yields, broad scope	Requires transition metals	Aryl-aryl, C-N bond formation
Click Chemistry	Bioorthogonal conditions	Limited to triazole products	Biocompatible linker synthesis
Amide Coupling	Robust, predictable	Potential racemisation	Peptide-mimetic linkers
Organocatalysis	Sustainable, stereoselective	Lower reaction rates	Enantioselective synthesis

Click Chemistry Applications:

Copper(I)-catalysed azide-alkyne cycloaddition (CuAAC) reactions have gained prominence due to their exceptional efficiency and bioorthogonal nature[20]. The resulting 1,2,3-triazole linkages provide metabolically stable, hydrogen-bond capable spacers that enhance pharmacokinetic properties whilst maintaining structural rigidity.

3.2 Synthetic Challenges and Solutions

The synthesis of architecturally complex hybrid molecules presents several challenges, including functional group incompatibility, stereochemical control, and scalability considerations[21]. Contemporary solutions involve computer-assisted retrosynthetic analysis to identify optimal synthetic routes and early recognition of potential incompatibilities[22].

Linker Design Optimisation:

The systematic optimisation of linker systems requires balancing conformational flexibility with chemical stability. Flexible linkers (alkyl chains, polyethylene glycol units) provide conformational adaptability, whilst rigid linkers (aromatic systems, heterocycles) enforce defined spatial orientations[23].

Table 3.Characteristics of linker systems in hybrid drug design

Linker Type	Length Range	Conformational Properties	Stability Profile	Optimal Applications
Alkyl Chains	2-12 atoms	High flexibility	Excellent	General MTDL construction
PEG Spacers	4-20 atoms	High flexibility	Excellent	Solubility enhancement
Aromatic Rings	6-12 atoms	Restricted rotation	Excellent	Defined geometry requirements
Triazole Units	3 atoms	Rigid planarity	Outstanding	Click chemistry products
Disulfide Bonds	2 atoms	Limited rotation	Reducible	Stimulus-responsive systems

4. MULTI- TARGET DIRECTED LIGANDS (MTDLs)

4.1 Design Principles and Target Selection

MTDLs represent the most extensively investigated class of hybrid anticancer agents, incorporating pharmacophoric elements designed to engage multiple therapeutically relevant targets simultaneously[24]. Successful MTDL design requires identification of target combinations that provide synergistic therapeutic benefits whilst maintaining acceptable selectivity profiles[25].

Kinase-Kinase Hybrid Inhibitors:

Dual kinase inhibitors exemplify successful MTDL implementation, with several candidates demonstrating superior efficacy compared to single-target analogues[26]. The design of these agents requires detailed analysis of ATP-binding site homology to identify conserved features that enable dual inhibition whilst preserving selectivity.

Kinase-Kinase Hybrid inhibitors



Dual EGFR/HER2 inhibitor

Figure3:Dual EGFR/HER2 inhibitor structure showing pharmacophoric elements and binding modes

Table 4.Major dual kinase inhibitor combinations in clinical development

Target Combination	Therapeutic Rationale	Development Status	Clinical Advantages
EGFR/HER2	Overcome receptor crosstalk	Phase II/III	Resistance prevention
CDK4/6-HDAC	Cell cycle and epigenetic control	Preclinical	Synergistic growth inhibition
PI3K/mTOR	Pathway feedback inhibition	Approved (multiple agents)	Complete pathway blockade
BCR-ABL/VEGFR	Anti-proliferative and anti-angiogenic	Approved (Ponatinib)	Dual mechanism efficacy

4.2 Epigenetic Hybrid Modulators

The integration of epigenetic regulatory mechanisms has emerged as a particularly promising strategy, given the fundamental role of chromatin modifications in oncogenesis[27]. HDAC-DNMT hybrid inhibitors represent prototypical examples, combining histone deacetylase inhibition with DNA methyltransferase blockade to achieve coordinated epigenetic reprogramming[28].



Figure4 : HDAC-DNMT hybrid structure showing zinc-binding domain, linker, and methyltransferase inhibitory moiety

5. DUAL MECHANISM HYBRID MOLECULES

5.1 Mechanistic Synergy and Design Rationale

Dual-mechanism hybrids exploit the therapeutic advantages of combining fundamentally distinct modes of action within a single molecular entity[29]. This approach is particularly valuable for addressing the mechanistic redundancy that often underlies therapeutic resistance in cancer treatment[30].

DNA-Alkylator/Topoisomerase Inhibitor Conjugates:

The combination of DNA cross-linking agents with topoisomerase inhibitors represents a paradigmatic example of mechanistic synergy. These hybrids induce cumulative genomic instability by simultaneously preventing DNA repair and enforcing strand breaks, leading to enhanced cytotoxicity[31].

Table 5. Mechanistic components and effects of DNA-targeting hybrid agents

Mechanistic Component	Primary Target	---Cellular Effect	Resistance Mechanisms Addressed
DNA Alkylation	Nucleotide bases	Interstrand crosslinks	Mismatch repair deficiency
Topoisomerase Inhibition	DNA-enzyme complex	Strand break accumulation	Efflux pump overexpression
Combined Action	Multiple DNA lesions	Synthetic lethality	Multidrug resistance

5.2 Resistance Circumvention Strategies

Efflux Pump Inhibitor-Cytotoxic Agent Hybrids:

The integration of P-glycoprotein inhibitory elements with cytotoxic pharmacophores addresses one of the most prevalent mechanisms of multidrug resistance[32]. These conjugates ensure sustained intracellular drug accumulation whilst delivering potent antiproliferative effects.

6. TARGETING -WARHEAD CONJUGATES

6.1 Selective Delivery Mechanisms

Targeting-warhead conjugates represent a sophisticated approach to achieving cancer cell selectivity through the covalent linkage of highly potent cytotoxic payloads with tumour-selective targeting moieties[33]. This strategy encompasses receptor-mediated targeting, enzyme-activated prodrug systems, and microenvironment-responsive delivery mechanisms[34].

Folate Receptor-Targeted Conjugates:

Folate receptor-targeted conjugates capitalise on the aberrant overexpression of folate receptors in numerous malignancies to achieve preferential drug delivery[35]. These systems typically incorporate folic acid or antifolate ligands coupled to potent cytotoxins through cleavable linker systems.

Table 6. Targeting strategies and clinical applications in conjugate therapy

Targeting Strategy	Receptor Expression---	Cancer Indications	Clinical Examples
Folate Receptor α	Ovarian (90%), lung (75%)	Platinum-resistant ovarian, NSCLC	Vintafolide, IMGN853
PSMA	Prostate (95%)	Metastatic castration-resistant prostate	PSMA-617, PSMA-1007
HER2	Breast (20%), gastric (15%)	HER2-positive malignancies	T-DM1, T-DXd

7. STRUCTURE-ACTIVITY RELATIONSHIP ANALYSIS

7.1 Quantitative SAR Approaches

The systematic analysis of structure-activity relationships in hybrid molecules requires sophisticated computational and experimental methodologies capable of addressing the inherent complexity of multi-target pharmacology[36]. Quantitative structure-activity relationship (QSAR) modelling has become indispensable for understanding the molecular determinants of hybrid bioactivity[37].

Molecular Descriptor Analysis:

The identification of physicochemical parameters that correlate with anticancer efficacy provides crucial insights for rational optimisation[38]. Key descriptors include lipophilicity (LogP), molecular weight, polar surface area, and hydrogen bonding capacity.

Table 7.Key molecular descriptors and optimal ranges for hybrid drug design

Molecular Descriptor	Optimal Range	Pharmacological Impact	Measurement Method
Lipophilicity (LogP)	2-5	Membrane permeability, distribution	Experimental/computational
Molecular Weight	400-800 Da	Oral bioavailability, tissue penetration	Mass spectrometry
Polar Surface Area	60-140 Ų	Passive diffusion, BBB permeation	Computational algorithms
Rotatable Bonds	≤10	Conformational entropy, binding	Structural analysis

8. CLINICAL APPLICATION AND CASE STUDY

8.1 Successful Clinical Candidates

Ponatinib: A Paradigmatic Dual Kinase Inhibitor

Ponatinib exemplifies successful hybrid design through its dual inhibition of BCR-ABL and vascular endothelial growth factor receptor (VEGFR) pathways[39]. This agent demonstrates exceptional potency against BCR-ABL mutations, including the clinically challenging T315I gatekeeper mutation, whilst providing anti-angiogenic activity[40].



Figure5 : Ponatinib structure

Table 8. Comparative pharmacological profile of ponatinib

Pharmacological Parameter	Ponatinib-	Imatinib (Reference)-	Clinical Advantage
BCR-ABL IC_{50} (nM)	0.37	260	700-fold enhanced potency
T315I mutant activity	Active (IC_{50} 2.0 nM)	Inactive	Overcomes resistance
VEGFR2 IC_{50} (nM)	1.5	>1000	Anti-angiogenic effects
Clinical response rate	70% (CP-CML)	95% (newly diagnosed)	Effective in resistant disease

8.2 Lessons from Clinical Development

The clinical development of hybrid molecules has provided valuable insights into the challenges and opportunities associated with multi-target approaches[41]. Pharmacokinetic optimisation emerges as a critical success factor, as the integration of multiple pharmacophoric elements often compromises drug-like properties[42].

9. FUTURE PERSPECTIVES AND EMERGING TRENDS

9.1 Artificial Intelligence in Hybrid Design

The integration of machine learning algorithms and artificial intelligence platforms is revolutionising hybrid drug discovery through enhanced prediction of multi-target activity profiles and optimisation of molecular properties[43]. Deep learning approaches enable autonomous molecular design with tailored pharmacological characteristics[44].

9.2 Precision Medicine Integration

The convergence of cancer genomics with hybrid drug design offers unprecedented opportunities for personalised therapeutic approaches[45]. Biomarker-driven patient selection and companion diagnostic development will likely define the next generation of hybrid therapeutics[46].

10. CONCLUSIONS

Molecular hybridisation represents a mature yet continuously evolving paradigm in anticancer drug design, offering significant potential to address the multifactorial nature of cancer through rational multi-target approaches. The evidence presented in this review demonstrates that successful hybridisation strategies can yield substantial improvements in therapeutic efficacy whilst maintaining acceptable safety profiles.

The progression from elementary dual-pharmacophore constructs to sophisticated multi-target directed ligands reflects our evolving understanding of cancer biology and drug design principles. Modern synthetic methodologies have facilitated access to increasingly complex hybrid architectures, whilst computational approaches enable rational optimisation of multi-target activity profiles.

Clinical translation challenges, particularly relating to pharmacokinetic optimisation and manufacturing complexity, remain significant obstacles. However, the successful advancement of several hybrid candidates through clinical development provides compelling validation of this approach. Future developments will likely be shaped by artificial intelligence-driven design, precision medicine integration, and advanced synthetic methodologies.

The establishment of standardised evaluation frameworks for multi-target agents remains essential for advancing the field. Such methodological harmonisation would enable more meaningful comparison of different hybridisation strategies and accelerate the

identification of optimal design principles. These advances position molecular hybridisation as a central strategy in the pursuit of next-generation anticancer therapeutics.

CONFLICT OF INTEREST

None

REFERENCES

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.

2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.

3. Proschak E, Stark H, Merk D. Polypharmacology by design: a medicinal chemist's perspective on multitargeting compounds. J Med Chem. 2019;62(2):420-444.

4. Viegas-Junior C, Danuello A, da Silva Bolzani V, Barreiro EJ, Fraga CA. Molecular hybridization: a useful tool in the design of new drug prototypes. Curr Med Chem. 2007;14(17):1829-1852.

5. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682-690.

6. Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005;48(21):6523-6543.

7. Zimmermann GR, Lehár J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007;12(1-2):34-42.

8. Anighoro A, Bajorath J, Rastelli G. Polypharmacology: challenges and opportunities in drug discovery. J Med Chem. 2014;57(19):7874-7887.

9. Ramsay RR, Popovic-Nikolic MR, Nikolic K, Uliassi E, Bolognesi ML. A perspective on multi-target drug discovery and design for complex diseases. Clin Transl Med. 2018;7(1):3.

10. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714-726.

11. Keith CT, Borisy AA, Stockwell BR. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov. 2005;4(1):71-78.

12. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546-1558.

13. Morphy R, Rankovic Z. The physicochemical challenges of designing multiple ligands. J Med Chem. 2006;49(16):4961-4970.

14. Keserű GM, Makara GM. The influence of lead discovery strategies on the properties of drug candidates. Nat Rev Drug Discov. 2009;8(3):203-212.

15. Hann MM, Keserű GM. Finding the sweet spot: the role of nature and nurture in medicinal chemistry. Nat Rev Drug Discov. 2012;11(5):355-365.

16. Gleeson MP, Hersey A, Montanari D, Overington J. Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat Rev Drug Discov. 2011;10(3):197-208.

17. Roughley SD, Jordan AM. The medicinal chemist's toolbox: an analysis of reactions used in the pursuit of drug candidates. J Med Chem. 2011;54(10):3451-3479.

18. Burke MD, Schreiber SL. A planning strategy for diversity-oriented synthesis. Angew Chem Int Ed Engl. 2004;43(1):46-58.

19. Magano J, Dunetz JR. Large-scale applications of transition metal-catalyzed couplings for the synthesis of pharmaceuticals. Chem Rev. 2011;111(3):2177-2250.

20. Kolb HC, Finn MG, Sharpless KB. Click chemistry: diverse chemical function from a few good reactions. Angew Chem Int Ed Engl. 2001;40(11):2004-2021.

21. Brown DG, Boström J. Analysis of past and present synthetic methodologies on medicinal chemistry: where have all the new reactions gone? J Med Chem. 2016;59(10):4443-4458.

22. Corey EJ, Wipke WT. Computer-assisted design of complex organic syntheses. Science. 1969;166(3902):178-192.

23. Wermuth CG. Selective optimization of side activities: another way for drug discovery. J Med Chem. 2004;47(6):1303-1314.

24. Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Melchiorre C. From dual binding site acetylcholinesterase inhibitors to multi-target-directed ligands (MTDLs): a step forward in the treatment of Alzheimer's disease. Mini Rev Med Chem. 2008;8(10):960-967.

25. Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M, Melchiorre C. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem. 2008;51(3):347-372.

26. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009;9(1):28-39.

27. Feinberg AP, Koldobskiy MA, Göndör A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Genet. 2016;17(5):284-299.

28. Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999;21(1):103-107.

29. Chabner BA, Roberts TG Jr. Timeline: chemotherapy and the war on cancer. Nat Rev Cancer. 2005;5(1):65-72.

30. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2(1):48-58.

31. Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020;83(3):770-803.

32. Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehár J, Price ER, Serbedzija G, Zimmermann GR, Foley MA, Stockwell BR, Keith CT. Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci USA. 2003;100(13):7977-7982.

33. Chari RV, Miller ML, Widdison WC. Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed Engl. 2014;53(15):3796-3827.

34. Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-337.

35. Elnakat H, Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev. 2004;56(8):1067-1084.

36. Hansch C, Leo A. Exploring QSAR: fundamentals and applications in chemistry and biology. American Chemical Society. 1995.

37. Tropsha A. Best practices for QSAR model development, validation, and exploitation. Mol Inform. 2010;29(6-7):476-488.

38. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1-3):3-26.

39. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J,

Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401-412.

40. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H; PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783-1796.

41. Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327-344.

42. Waring MJ. Lipophilicity in drug discovery. Expert Opin Drug Discov. 2010;5(3):235-248.

43. Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. Drug Discov Today. 2018;23(6):1241-1250.

44. Schneider G. Automating drug discovery. Nat Rev Drug Discov. 2018;17(2):97-113.

45. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793-795.

46. Simon R, Roychowdhury S. Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov. 2013;12(5):358-369.